Jefferies Group LLC Blueprint Medicines Corp Call Options Transaction History

Jefferies Group LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2021 May 14, 2021	SELL	$90.71 - $108.28 $4.24 Million - $5.06 Million	-46,700 Closed	0 $0
Q4 2020 Sep 21, 2023	BUY	$92.08 - $124.48 $4.3 Million - $5.81 Million	46,700 New	46,700 $5.24 Million
Q4 2020 Feb 16, 2021	SELL	$92.08 - $124.48 $3.09 Million - $4.18 Million	-33,600 Reduced 41.84%	46,700 $5.24 Million
Q3 2020 Nov 13, 2020	BUY	$66.45 - $92.7 $3.84 Million - $5.36 Million	57,800 Added 256.89%	80,300 $7.44 Million
Q2 2020 Aug 14, 2020	BUY	$57.09 - $79.27 $416,757 - $578,671	7,300 Added 48.03%	22,500 $1.76 Million
Q1 2020 May 15, 2020	SELL	$48.11 - $82.22 $1.91 Million - $3.27 Million	-39,800 Reduced 72.36%	15,200 $889,000
Q4 2019 Feb 13, 2020	SELL	$66.73 - $82.59 $66,730 - $82,590	-1,000 Reduced 1.79%	55,000 $4.41 Million
Q3 2019 Nov 13, 2019	BUY	$72.9 - $101.41 $3.65 Million - $5.07 Million	50,000 Added 833.33%	56,000 $4.11 Million
Q2 2019 Aug 14, 2019	BUY	$73.54 - $97.8 $441,240 - $586,800	6,000 New	6,000 $566,000
Q3 2018 Nov 14, 2018	SELL	$58.91 - $78.32 $1.77 Million - $2.35 Million	-30,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $1.83 Million - $3.04 Million	30,000 New	30,000 $1.9 Million

355

60.7M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $6.72B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.